Medicines & Healthcare products Regulatory Agency



Influenza Reagent Influenza Virus Infectious X-361A (H3N2) NIBSC code: 21/190 Instructions for use (Version 2.0, Dated 11/07/2022)

§

1. INTENDED USE

Reagent 21/190 is prepared from X-361A, a HGR derived from A/Cambodia/E0826360/2020 (H3N2) which was processed in 250 μ l volumes as liquid stock. The derivation and known passage history of X-361A (H3N2) is attached.

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain

The material is not of human or bovine origin.

3. UNITAGE

No unitage is assigned to this material

4. CONTENTS

 $\begin{array}{l} \mbox{Country of origin of biological material: United Kingdom.} \\ \mbox{Each vial contains $250 \mu I (nominal) of infectious influenza virus as} \\ \mbox{allantoic fluid from SPF embryonated hen's eggs.} \end{array}$

5. STORAGE

Store in the dark at -700C or below

6. DIRECTIONS FOR OPENING

Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

7. USE OF MATERIAL

Ready to use

8. STABILITY

Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES

NA

10. ACKNOWLEDGEMENTS

NA

11. FURTHER INFORMATION

Further information can be obtained as follows; This material: enquiries@nibsc.org WHO Biological Standards: http://www.who.int/biologicals/en/ JCTLM Higher order reference materials:

National Institute for Biological Standards and Control,

Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards, UK Official Medicines Control Laboratory http://www.bipm.org/en/committees/jc/jctIm/ Derivation of International Units: http://www.nibsc.org/standardisation/international_standards.aspx Ordering standards from NIBSC: http://www.nibsc.org/products/ordering.aspx NIBSC Terms & Conditions: http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties					
Physical appearance: Clear liquid		Corrosive:	No		
Stable:	Yes	Oxidising:	No		
Hygroscopic:	No	Irritant:	No		
Flammable:	No	Handling:See	caution, Section 2		
Other (specify):	Live influenza virus				

Toxicological properties

	-	
Effects of inhalation:	Likelihood of influenza virus infection	
Effects of ingestion:	Not established, avoid ingestion	
Effects of skin	Not established, avoid contact with	
absorption:	skin	

Suggested First Aid		
Inhalation:	Seek medical advice	
Ingestion:	Seek medical advice	
Contact with	Wash with copious amounts of water. Seek	
eyes:	medical advice	
Contact with skin:	Wash thoroughly with water.	

Action on Spillage and Method of Disposal

Spillage of contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with an appropriate virucidal agent followed by water. Absorbent materials used to treat spillage should be treated as biologically hazardous waste.

15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all

Medicines & Healthcare products Regulatory Agency



other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom			
* Defined as the country where the goods have been produced			
and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze- drying.			
Net weight: 0.25g per vial			
Toxicity Statement: Non-toxic			

Toxicity Statement: Non-toxic Veterinary certificate or other statement if applicable. Attached: No

Cumulative number of passages	Passage numbers at each stage	Lot	Laboratory
E1-E4	E4	Unknown	Unknown
E5	E5	10041568	VIDRL, Australia
E14	E5/E9	E#6480	NYMC, US
E15	E5/E9/E1	46280	NIBSC, UK

Passage history of X-361A (H3N2)

Sterility: No visible contamination was detected in a variety of media (tryptose soya broth, thioglycolate broth, Sabouraud's broth and blood agar plates) after 14 days incubation.

The HA and NA sequence of this virus is available at GISAID with the accession number EPI_ISL_3039335.

Derivation of NYMC X-361 High Yield H3N2 Reassortant (6:2) with A/PR/8/34 PB1, PB2, PA, NP, NS and M genes and A/Cambodia/e0826360/2020 HA and NA genes


Experiment # 4869 (2/8/2021) A/Cambodia/e0826360/2020 (H3N2) E5 #SL10041568 7/16/2020 12/23/20

1

Passages prior to receipt at NYMC -5

Passages at New York Medical College

Passage No.



National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards, UK Official Medicines Control Laboratory



A/Cambodia/e0826360/2020 (H3N2) x A/PR/8/34 10⁻³ 2 10⁻² + HA-1:1024 3 10⁻¹ + A/PR/8/34 antisera (as) A/PR/8/34 HANA antibodies (ab) <u>HA-1:512</u> 10⁻¹ + A/PR/8/34 antisera (as) 4 A/PR/8/34 HANA antibodies (ab) HA-1:16 5 10⁻² + A/PR/8/34 antisera (as) A/PR/8/34 HANA antibodies (ab) HA _1.**1**6 6 10⁻³ <u>HA-1:1024</u> 7 10⁻⁸ HA - 1:1024 10-8 8 HA-1:256 9 10-5 HA-1:256 NYMC X- 361A (E5/E2/E9) E#6480

Reassortment passage at NYMC

HA and NA genes were identified as A/Cambodia/e0826360/2020 by RT-PCR/RFLP gene analysis. PB2, PB1, PA, NS, NP and M genes were identified as A/PR/8/34 by RT-PCR/RFLP analysis.

The HA yield for X-361A was shown to be 4.6 ug/ml by UPLC analysis. The HA yield for A/Cambodia/e0826360/2020 was 2.8 ug/ml by UPLC analysis. The fold increase was 1.64.

SPF eggs were used for all reassortant passages.

All HA titers were tested using guinea pig red blood cells (cRBC) at room temperature.

Virus seed was shown to be sterile. Sterility testing was performed by streaking the sample on blood agar plates and incubating for 48 hours at 37 °C.

National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards, UK Official Medicines Control Laboratory





A/Cambodia/e0826360/2020 = 2.8 ug/ml NYMC X-361A = 4.6 ug/ml Fold Increase in yield — 1.64